NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Proposed Single Technology Appraisal (STA)

Regorafenib for the treatment of metastatic colorectal cancer following prior treatment for metastatic disease

Provisional matrix of consultees and commentators

Consultees		Co	Commontators (no right to submit or	
Consumees		Commentators (no right to submit or appeal)		
Manufacturers/sponsors		General		
1010	Bayer (regorafenib)	•	Allied Health Professionals Federation	
	Dayor (rogoraroriis)	•	Board of Community Health Councils in	
Pa	atient/carer groups		Wales	
•	Afiya Trust	•	British National Formulary	
•	Beating Bowel Cancer	•	Care Quality Commission	
•	Black Health Agency	•	Commissioning Support Appraisals	
•	Bladder and Bowel Foundation		Service	
•	Bowel Cancer Information (formerly	•	Department of Health, Social Services	
	Lynn's Bowel Cancer Campaign)		and Public Safety for Northern Ireland	
•	Bowel Cancer UK	•	Healthcare Improvement Scotland	
•	Cancer Black Care	•	Medicines and Healthcare products	
•	Cancer Equality		Regulatory Agency	
•	Colostomy Association	•	National Association of Primary Care	
•	Counsel and Care	•	National Pharmacy Association	
•	Equalities National Council	•	NHS Alliance	
•	Helen Rollason Heal Cancer Charity	•	NHS Commercial Medicines Unit	
•	IA (Ileostomy and Internal Pouch	•	NHS Confederation	
	Support Group)	•	Public Health Wales NHS Trust	
•	Macmillan Cancer Support	•	Scottish Medicines Consortium	
•	Maggie's Centres			
•	Marie Curie Cancer Care		ssible comparator manufacturers	
•	Muslim Council of Britain	•	None	
•	Muslim Health Network			
•	Ostomy Lifestyle	-	elevant research groups	
•	South Asian Health Foundation	•	Cochrane Colorectal Cancer Group	
•	Specialised Healthcare Alliance	•	CORE- Digestive Disorders Foundation	
•	Tenovus	•	Institute of Cancer Research	
_		•	MRC Clinical Trials Unit	
<u>Pr</u>	ofessional groups	•	National Cancer Research Institute	
•	Association of Cancer Physicians	•	National Cancer Research Network	
•	Association of Coloproctologists of	•	National Institute for Health Research	
	Great Britain	•	Research Institute for the Care of Older	
•	British Association for Services to the		People	
_	Elderly Pritish Corietries Society			
•	British Geriatrics Society			
•	British Institute for Radiology			

National Institute for Health and Clinical Excellence

Provisional matrix for the proposed technology appraisal of regorafenib for the treatment of metastatic colorectal cancer following prior treatment for metastatic disease

Issue date: November 2012 Page 1 of 3

Consultees Commentators (no right to submit or appeal) **Evidence Review Group** British Psychosocial Oncology Society (BPOS) Evidence Review Group tbc British Society of Gastroenterology National Institute for Health Research Cancer Network Pharmacists Forum Health Technology Assessment Programme Cancer Research UK Royal College of General Practitioners Associated Guideline Groups Royal College of Nursing National Collaborating Centre for Royal College of Pathologists Cancer Royal College of Physicians Royal College of Radiologists Associated Public Health Groups Royal Pharmaceutical Society tbc Royal Society of Medicine Society and College of Radiographers United Kingdom Clinical Pharmacy Association United Kingdom Oncology Nursing Society Others Department of Health South of Tyne & Weir PCT Cluster Tees PCT Cluster Welsh Government

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Issue date: November 2012

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; Healthcare Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary.

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

Evidence Review Group (ERG)

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.

National Institute for Health and Clinical Excellence
Provisional matrix for the proposed technology appraisal of regorafenib for the treatment of metastatic colorectal cancer following prior treatment for metastatic disease
Issue date: November 2012

Page 3 of 3

¹ Non manufacturer consultees are invited to submit statements relevant to the group they are representing.